Avatrombopag
- Generic Name
- Avatrombopag
- Brand Names
- Doptelet 60 Mg Daily Dose Carton, Doptelet
- Drug Type
- Small Molecule
- Chemical Formula
- C29H34Cl2N6O3S2
- CAS Number
- 570406-98-3
- Unique Ingredient Identifier
- 3H8GSZ4SQL
- Background
Avatrombopag (Doptelet), is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation , . This decreases the need for blood transfusions .
...
- Indication
Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure .
- Associated Conditions
- Thrombocytopenia
- Associated Therapies
- -
Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04896528
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 46
- Registration Number
- NCT04797182
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Anhui Provincial Cancer Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT04609891
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
- Conditions
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Sobi, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT04516967
- Locations
- 🇺🇸
Site 116, Atlanta, Georgia, United States
🇺🇸Site 114, Jackson, Mississippi, United States
🇺🇸Site 121, Philadelphia, Pennsylvania, United States
Avatrombopag for Thrombocytopenia in People With Cancer
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT04437953
Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Ayman Saad
- Registration Number
- NCT04312789
Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure
- Conditions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Sobi, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03554759
- Locations
- 🇺🇸
Dova Site, Philadelphia, Pennsylvania, United States
🇺🇸Dova Study Site, Milwaukee, Wisconsin, United States
🇺🇸Dova Study SIte, Roanoke, Virginia, United States
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Sobi, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT03471078
- Locations
- 🇺🇦
Dova Site, Vinnytsia, Ukraine
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02809768
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT02227693
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.